BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin

Biotech Investing

BeyondSpring (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company has initiated the Phase 3 portion of Study 105 evaluating its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia (CIN) associated with docetaxel, a cytotoxic chemotherapeutic. CIN is a common side effect of many cancer …

BeyondSpring (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company has initiated the Phase 3 portion of Study 105 evaluating its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia (CIN) associated with docetaxel, a cytotoxic chemotherapeutic. CIN is a common side effect of many cancer chemotherapies, and results from the destruction of neutrophils (a type of white blood cell that is critical in defense against infections).

As quoted in the press release:

Dr. Blayney, Professor of Medicine at Stanford University, noted, “There have been minimal advancements in the treatment of CIN in the past 30 years, and patients will benefit from new approaches that can overcome the limitations associated with current practice. The goal of neutropenia therapy is to reduce potentially life-threatening infections associated with chemotherapy. Reducing the duration of severe neutropenia (DSN), which lowers the amount of time chemotherapy patients are at infection risk, predicts patient benefit. Reduction of DSN to less than one day is clinically meaningful. In the Phase 2 portion of Study 105, Plinabulin achieved the target DSN reduction.”

Click here to read the full press release.

The Conversation (0)
×